Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07313670
NA

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Sponsor: Muhammad Aamir Latif

View on ClinicalTrials.gov

Summary

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Key Details

Gender

All

Age Range

2 Months - 12 Years

Study Type

INTERVENTIONAL

Enrollment

122

Start Date

2026-01-01

Completion Date

2026-06-30

Last Updated

2026-01-02

Healthy Volunteers

No

Conditions

Interventions

DRUG

Intravenous Hydrocortisone

Children will receive early intravenous hydrocortisone at 2 mg/kg/day divided every 6 hours, continued for 7 days or until resolution of shock.

DRUG

Standard care

The children will be managed by following standard institutional treatment protocol.

Locations (1)

Abbasi Shaheed Hospital

Karachi, Sindh, Pakistan